Sun Pharma Advanced Research Company (SPARC) Q1 24/25 earnings summary

Executive summary

• Total income for the quarter ended June 30, 2024, was ₹1,837 lakhs, down from ₹3,414 lakhs year-over-year and ₹2,096 lakhs sequentially.

• Net loss for the quarter was ₹9,585 lakhs, compared to a net loss of ₹9,501 lakhs in the same quarter last year and ₹10,661 lakhs in the previous quarter.

• The company continues to operate as a going concern, supported by unutilized credit limits and a financial support letter from its promoter group entity.

Financial highlights

• Revenue from operations for the quarter was ₹1,681 lakhs, a decrease from ₹2,395 lakhs year-over-year and slightly up from ₹1,656 lakhs sequentially.

• Other income declined to ₹156 lakhs from ₹1,019 lakhs year-over-year and ₹440 lakhs sequentially.

• Total expenses for the quarter were ₹11,387 lakhs, compared to ₹12,949 lakhs year-over-year and ₹12,637 lakhs sequentially.

• Basic and diluted loss per share for the quarter was ₹2.96, compared to ₹2.94 year-over-year and ₹3.26 sequentially.

Outlook and guidance

• The company has received assurance of continued financial support from its promoter group entity to maintain operations and status as a going concern.